Abstract
Airborne infections constitute an extensive group of human diseases. The first barrier to the penetration of infectious agents is the oropharyngeal mucosa, where the autonomic immune system plays a special role. Therefore, maintaining the active function of mucosal immunity and its correction in situ, in the focus of inflammation, is an important way to stop respiratory infections. The coronavirus pandemic has spurred the search for effective means of preventing and treating viral diseases. Various nasal formulations have been proposed with barrier, virucidal, anti-inflammatory and antibacterial properties. An important place belongs to antibodies directed against a specific pathogen, for which it is proposed to use monoclonal antibodies, antibodies isolated from eggs of immunized chickens, nano-antibodies of representatives of the Camelid family, or colostrum antibodies of vaccinated cows. In our opinion, it is more attractive to use antibodies isolated from human blood plasma, which have a wide spectrum of activity, therefore, in the case of mixed infection or difficult diagnosis, they can have a preventive or therapeutic effect against many pathogens. Nasal drops or spray containing human immunoglobulin can be an effective treatment for many bacterial and viral infections, including COVID-19. Key words: аirborne infections, COVID-19, prevention, nasal drugs, antibodies, human immunoglobulin
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
